Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | AXL |
| Variant | positive |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | AXL positive indicates the presence of AXL mRNA and/or protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
AXL positive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | Ewing sarcoma | sensitive | Bemcentinib | Preclinical - Cell culture | Actionable | In a preclinical study, Bemcentinib (BGB-324) inhibited growth of Ewing sarcoma cell lines positive for Axl expression in culture (PMID: 25528764). | 25528764 |
| AXL positive | head and neck squamous cell carcinoma | sensitive | Bemcentinib | Preclinical | Actionable | In a preclinical study, Bemcentinib (BGB-324) inhibited proliferation and invasion of head and neck squamous cell carcinoma cell lines positive for Axl expression in culture (PMID: 25767293). | 25767293 |
| AXL positive | head and neck squamous cell carcinoma | sensitive | Bemcentinib + Cetuximab | Preclinical | Actionable | In a preclinical study, BGB-324 and Erbitux (cetuximab) worked synergistically to inhibit proliferation of Axl-positive head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293). | 25767293 |
| AXL positive | breast cancer | sensitive | Bemcentinib | Preclinical | Actionable | In a preclinical study, Bemcentinib (BGB-324) inhibited tumor growth and metastasis in xenograft models of Axl-positive breast cancer cell lines, resulting in prolonged survival (PMID: 20145120). | 20145120 |
| AXL positive | triple-receptor negative breast cancer | sensitive | Dubermatinib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a triple-receptor negative breast cancer cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). | 27671334 |
| AXL positive | lung non-small cell carcinoma | sensitive | Dubermatinib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a non-small cell lung carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). | 27671334 |
| AXL positive | head and neck squamous cell carcinoma | sensitive | Dubermatinib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, a head and neck squamous cell carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). | 27671334 |
| AXL positive | triple-receptor negative breast cancer | sensitive | Bemcentinib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an AXL-expressing triple-receptor negative breast cancer cell line demonstrated greater sensitivity to the combination of Bemcentinib (BGB-324) and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334). | 27671334 |
| AXL positive | lung non-small cell carcinoma | sensitive | Bemcentinib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, an AXL-expressing non-small cell lung carcinoma cell line demonstrated greater sensitivity to the combination of BGB-324 and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334). | 27671334 |
| AXL positive | glioblastoma | sensitive | BMS-777607 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BMS-777607 inhibited Axl phosphorylation, resulted in decreased viability of glioblastoma multiforme cell lines in culture and in cell line xenograft models (PMID: 26848524). | 26848524 |
| AXL positive | acute myeloid leukemia | sensitive | Bemcentinib | Phase I | Actionable | In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in complete response in 12.5% (1/8), partial response in 12.5% (1/8), and stable disease in 37.5% (3/8) of acute myeloid leukemia patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). | detail... |
| AXL positive | myelodysplastic syndrome | sensitive | Bemcentinib | Phase I | Actionable | In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in stable disease in 100% (3/3) of myelodysplastic syndrome patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). | detail... |
| AXL positive | Advanced Solid Tumor | predicted - sensitive | Enapotamab vedotin | Preclinical - Pdx | Actionable | In a preclinical study, Enapotamab vedotin (HuMax-Axl-ADC) inhibited tumor growth in solid tumor xenograft models, including induction of tumor regression in solid tumor patient-derived xenograft (PDX) models expressing Axl in a subset of tumor cells (J Clin Onc 2015 33:15_suppl, 3066). | detail... |
| AXL positive | triple-receptor negative breast cancer | sensitive | 20G7-D9 | Preclinical - Pdx | Actionable | In a preclinical study, 20G7-D9 inhibited tumor growth in triple-negative breast cancer cell line xenograft models with high or moderate AXL expression and in AXL-expressing patient-derived xenograft (PDX) models (PMID: 27923843). | 27923843 |
| AXL positive | chronic myeloid leukemia | sensitive | AXL CAR-T cells | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with AXL CAR-T cells led to induced death of AXL-expressing chronic myeloid leukemia (CML) cells and did not induce death of AXL-negative CML cells in culture (PMID: 29497107). | 29497107 |
| AXL positive | lung non-small cell carcinoma | unknown | INCB081776 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, INCB081776 inhibited Axl phosphorylation in tumor, enhanced anti-tumor immune response, inhibited tumor growth in immunocompetent, but not immunodeficient mouse models of non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 3759). | detail... |
| AXL positive | triple-receptor negative breast cancer | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive triple-negative breast cancer cell line in culture and resulted in complete responses in 4/10, partial responses in 5/10, and tumor-free survival in 4/10 cell line xenograft models (PMID: 35086955). | 35086955 |
| AXL positive | renal cell carcinoma | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with ADCT-601 induced DNA interstrand crosslinking and inhibited growth of an AXL-positive renal cell carcinoma cell line in culture and at the highest tested dose resulted in a partial response in 1/8, complete responses in 7/8, and tumor-free survival in 6/8 cell line xenograft models (PMID: 35086955). | 35086955 |
| AXL positive | pancreatic cancer | sensitive | ADCT-601 | Preclinical - Pdx | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive pancreatic cancer cell line in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 35086955). | 35086955 |
| AXL positive | esophageal cancer | sensitive | ADCT-601 | Preclinical - Pdx | Actionable | In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive esophageal cancer cell line in culture and resulted in complete responses in 2/8, partial responses in 5/8, and tumor-free survival in 2/8 patient-derived xenograft (PDX) models (PMID: 35086955). | 35086955 |
| AXL positive | glioblastoma | sensitive | ADCT-601 | Preclinical - Cell culture | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive glioblastoma cell line in culture (PMID: 35086955). | 35086955 |
| AXL positive | lung adenocarcinoma | sensitive | ADCT-601 | Preclinical - Cell culture | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive lung adenocarcinoma cell line in culture (PMID: 35086955). | 35086955 |
| AXL positive | ovary adenocarcinoma | sensitive | ADCT-601 | Preclinical - Cell culture | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive ovarian adenocarcinoma cell line in culture (PMID: 35086955). | 35086955 |
| AXL positive | lung non-small cell carcinoma | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive non-small cell lung cancer cell line in culture and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 35086955). | 35086955 |
| AXL positive | Advanced Solid Tumor | sensitive | ER-851 | Preclinical - Cell culture | Actionable | In a preclinical study, ER-851 decreased viability of transformed cells expressing AXL in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 36279567). | 36279567 |